Crispr Therapeutics Ag (CRSP)
$44.38 3.09 (7.48%)
19:28 EDT CRSP Stock Quote Delayed 20 Minutes
Previous Close $44.38
Market Cap 2.08B
PE Ratio -
Volume (Avg. Vol.) 1.76M
Day's Range 39.25 - 44.65
52-Week Range 32.30 - 74.00
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
By Ian Cooper
The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Biotech stocks targeting gene therapy are going to be huge. Here are 3 gene therapy stocks to buy that have a ton of potential.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
No matter what risks you think lay ahead for the market (trade war, rate hikes, government shutdown), none of them hurt gene therapy stocks
The future of genetic medicine is bright, but bumpy. But these bumps will provide many opportunities to buy DNA stocks along the way.
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
The biotechnology and pharmaceutical sectors continue to offer great value for investors, and these five Big Pharma stocks stand out from the crowd.
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
From Market News Video
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available this week, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new May 22nd contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader